Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 September 2005Website:
http://www.viracta.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 46 min agoDividend
Analysts recommendations
Institutional Ownership
VIRX Latest News
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced that Michael Faerm has been appointed as the new Chief Financial Officer and was granted a non-qualified stock option to purchase 500,000 shares of common stock. The Board of Directors also approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. The options vest over four years, with 25% vesting on May 13, 2025, and the remaining 75% vesting in equal monthly increments over the next 36 months, contingent on continuous service to Viracta. The exercise price for each option is $0.804 per share, based on the closing price on May 14, 2024.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.
What type of business is Viracta Therapeutics?
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
What sector is Viracta Therapeutics in?
Viracta Therapeutics is in the Healthcare sector
What industry is Viracta Therapeutics in?
Viracta Therapeutics is in the Biotechnology industry
What country is Viracta Therapeutics from?
Viracta Therapeutics is headquartered in United States
When did Viracta Therapeutics go public?
Viracta Therapeutics initial public offering (IPO) was on 27 September 2005
What is Viracta Therapeutics website?
https://www.viracta.com
Is Viracta Therapeutics in the S&P 500?
No, Viracta Therapeutics is not included in the S&P 500 index
Is Viracta Therapeutics in the NASDAQ 100?
No, Viracta Therapeutics is not included in the NASDAQ 100 index
Is Viracta Therapeutics in the Dow Jones?
No, Viracta Therapeutics is not included in the Dow Jones index
When does Viracta Therapeutics report earnings?
The next expected earnings date for Viracta Therapeutics is 14 August 2024